Microbicidal heterocycles

Information

  • Patent Grant
  • 8748431
  • Patent Number
    8,748,431
  • Date Filed
    Friday, November 25, 2011
    13 years ago
  • Date Issued
    Tuesday, June 10, 2014
    10 years ago
Abstract
Compounds of the formula I Formula (I) wherein the substituents are as defined in claim 1, are useful as active ingredients, which have microbiocidal activity, in particular fungicidal activity.
Description

This application is a 371 of International Application No. PCT/EP2011/071037 filed Nov. 25, 2011, which claims priority to EP 10192493.4 filed Nov. 25, 2010, and 11153989.6 filed Feb. 10, 2011, the contents of which are incorporated herein by reference.


The present invention relates to heterocycles, e.g. as active ingredients, which have microbiocidal activity, in particular fungicidal activity. The invention also relates to preparation of these heterocycles, to heterocyclic derivatives used as intermediates in the preparation of these heterocycles, to preparation of these intermediates, to agrochemical compositions which comprise at least one of the heterocycles, to preparation of these compositions and to use of the heterocycles or compositions in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi.


Certain heterocycles for use as fungicides are described in WO 2007/014290, WO 2008/013622, WO 2008/013925, WO 2008/091580, WO 2008/091594 and WO 2009/055514.


The present invention provides compounds of formula




embedded image



wherein


G1 and G2 are independently O or S;


T is CR13 or N;


Y1 and Y2 are independently CR14 or N;


Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z, —C(═O)—N(R15)-z or —C(═S)—N(R16)-z, in each case z indicates the bond that is connected to R12;


n is 1 or 2;


p is 1 or 2, providing that when n is 2, p is 1;


R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, halogen, cyano, C1-C4alkyl or C1-C4haloalkyl;


R11, R15 and R16 each independently are hydrogen, C1-C4alkyl, C3-C5cycloalkyl or C1-C4alkoxy;


R12 is heteroaryl, heteroarylalkyl, or is group (a)




embedded image



wherein the heteroaryl and heteroarylalkyl can be optionally substituted with 1 to 4 R23,


each R23 independently is halogen, hydroxyl, cyano, mercapto, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, N(R24)2, phenyl or heteroaryl, wherein the phenyl and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; and


each R24 independently is hydrogen, cyano, C1-C4alkyl, C1-C4alkylcarbonyl, C1-C4haloalkylcarbonyl, C1-C4alkylsulfonyl or C1-C4haloalkylsulfonyl;


or a salt or a N-oxide thereof.


Where substituents are indicated as being optionally substituted, this means that they may or may not carry one or more identical or different substituents. Normally not more than three such optional substituents are present at the same time.


The term “halogen” refers to fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.


Alkyl substituents may be straight-chained or branched. Alkyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and the isomers thereof, for example, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-amyl or pivaloyl.


A haloalkyl group may contain one or more identical or different halogen atoms and, for example, may stand for CH2Cl, CHCl2, CCl3, CH2F, CHF2, CF3, CF3CH2, CH3CF2, CF3CF2 or CCl3CCl2.


Heteroaryl stands for aromatic ring systems comprising mono-, bi- or tricyclic systems wherein at least one oxygen, nitrogen or sulfur atom is present as a ring member. Monocyclic and bicyclic aromatic ring systems are preferred. For example, monoyclic heteoraryl may be a 5- to 7-membered monocyclic aromatic ring containing one to three heteroatoms selected from oxygen, nitrogen and sulfur, more preferably selected from nitrogen and sulfur. Bicyclic heteroaryl may be a 9- to 11-membered bicyclic ring containing one to five heteroatoms, preferably one to three heteroatoms, selected from oxygen, nitrogen and sulfur. Examples are furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, indazolyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, imiazothiazoyl, quinolinyl, quinoxalinyl, isoquinolinyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl and naphthyridinyl. Heteroaryl rings do not contain adjacent oxygen ring atoms, adjacent sulfur ring atoms or adjacent oxygen and sulfur ring atoms. A link to a heteroaryl group can be via a carbon atom or via a nitrogen atom.


Heteroarylalkyl means a group A-B—, wherein A is a heteroaryl group as defined above and B is an alkyl group as defined above. An example is heteroaryl-C1-C4alkyl, e.g. heteroaryl-methyl. Pyridyl-methyl- is a specific example. The presence of one or more possible asymmetric carbon atoms in a compound of formula I means that the compounds may occur in optically isomeric forms, i.e. enantiomeric or diastereomeric forms. Also atropisomers may occur as a result of restricted rotation about a single bond. Formula I is intended to include all those possible isomeric forms and mixtures thereof. The present invention includes all those possible isomeric forms and mixtures thereof for a compound of formula I. Likewise, formula I is intended to include all possible tautomers. The present invention includes all possible tautomeric forms for a compound of formula I.


In each case, the compounds of formula I according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form.


N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.


Suitable salts of the compounds of formula I include those resulting after addition of acid such as those with an inorganic mineral acid e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid, or an organic carboxylic acid e.g. oxalic, tartaric, lactic, butyric, toluic, hexanoic or phthalic acid, or a sulfonic acid e.g. methane, benzene or toluene sulfonic acid.


Preferably, the compound of formula I is a compound wherein:


G1 and G2 are independently O or S;


T is CR13 or N;


Y1 is N;


Y2 is CR14 or N;


Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z, —C(═O)—N(R15)-z or —C(═S)—N(R16)-z, in each case z indicates the bond that is connected to R12;


n is 1 or 2;


p is 1;


R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, halogen, C1-C4alkyl or C1-C4haloalkyl;


R11, R15 and R16 each independently are hydrogen, C1-C4alkyl or C1-C4alkoxy;


R12 is heteroaryl which can be optionally substituted with 1 to 3 R23, or is group (a);


each R23 independently is halogen, hydroxyl, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, N(R24)2, phenyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein the phenyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidinyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; and


each R24 independently is hydrogen, C1-C4alkyl, C1-C4alkylcarbonyl, C1-C4alkylsulfonyl or Cr C4haloalkylsulfonyl.


More preferably, the compound of formula I is a compound wherein:


G1 is O;


G2 is O or S;


T is CR13 or N;


Y1 is N;


Y2 is CR14 or N;


Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z or —C(═O)—N(R15)-z, in each case z indicates the bond that is connected to R12;


n is 1 or 2;


p is 1;


R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, C1-C4alkyl or C1-C4haloalkyl;


R11 and R15 each independently are hydrogen or C1-C4alkyl;


R12 is heteroaryl which can be optionally substituted with 1 to 3 R23, or is group (a);


each R23 independently is halogen, hydroxyl, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, N(R24)2, phenyl or pyridyl, wherein the phenyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; and


each R24 independently is hydrogen, C1-C4alkyl, C1-C4alkylcarbonyl or C1-C4alkylsulfonyl.


More preferably, the compound of formula I is a compound wherein:


G1 is O;


G2 is S;


T is CH or N;


Y1 is N;


Y2 is CH or N;


Q is —C(═O)-z, —C(═S)-z or —C(═O)—N(R15)-z, in each case z indicates the bond that is connected to R12;


n is 1 or 2;


p is 1;


R1 and R2 each independently are hydrogen, methyl or trifluoromethyl;


R3, R4, R5, R6, R7, R8, R9 and R10 each independently are hydrogen or methyl;


R11 and R15 each independently are hydrogen or methyl;


R12 is furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl, or is group (a), wherein the furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl and quinoxalinyl are optionally substituted with 1 to 3 R23;


each R23 independently is halogen, hydroxyl, cyano, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, N(R24)2, phenyl or pyridyl, wherein the phenyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy; and


each R24 independently is hydrogen or C1-C4alkylsulfonyl.


More preferably, the compound of formula I is a compound wherein:


G1 is O;


G2 is S;


T is CH;


Y1 is N;


Y2 is CH;


Q is —C(═O)-z or —C(═S)-z in each case z indicates the bond that is connected to R12;


n is 2;


p is 1;


R1 and R2 each independently are hydrogen, methyl or trifluoromethyl;


R3, R4, R5, R6, R7, R8, R9 and R10 each independently are hydrogen or methyl;


R11 is hydrogen or methyl; and


R12 is thiadiazolyl or pyridyl, wherein the thiadiazolyl and pyridyl are each optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, C1-C4alkyl and C1-C4alkoxy.


More preferably, the compound of formula I is a compound wherein:


G1 is O;


G2 is S;


T is CH;


Y1 is N;


Y2 is CH;


Q is —C(═O)-z, z indicates the bond that is connected to R12;


n is 2;


p is 1;


R1 is trifluoromethyl;


R2 is methyl;


R3, R4, R5, R6, R7, R8, R9 and R10 each independently are hydrogen;


R11 is hydrogen; and


R12 is pyridyl, optionally substituted with 1 to 3 substituents independently selected from halogen and hydroxyl.


The following list provides definitions, including preferred definitions, for substituents G1, G2, T, Y1, Y2, Q, n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R23 and R24 with reference to compounds of formula I. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document. The invention includes compounds of formula having all possible combinations of substituent definitions given below. Generally, in this document any substituent definition may be combined with any other substituent definition.


G1 and G2 are independently O or S. Preferably, G1 is O. Preferably, G2 is S.


T is CR13 or N. Preferably, T is CH or N, more preferably T is CH.


Y1 and Y2 are independently CR14 or N. Preferably, Y1 is N. Preferably, Y2 is CR14 or N, more preferably Y2 is CH or N, even more preferably Y2 is CH.


Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z, —C(═O)—N(R15)-z or —C(═S)—N(R16)-z, in each case z indicates the bond that is connected to R12. Preferably, Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z or —C(═O)—N(R15)-z. More preferably, Q is —C(═O)-z, —C(═S)-z or —C(═O)—N(R15)-z. More preferably, Q is —C(═O)-z or —C(═S)-z. Even more preferably, Q is —C(═O)-z.


n is 1 or 2, preferably n is 2.


p is 1 or 2, providing that when n is 2, p is 1, preferably p is 1.


R1 and R2 each independently are hydrogen, halogen, cyano, C1-C4alkyl or C1-C4haloalkyl. Preferably, R1 and R2 each independently are hydrogen, halogen, C1-C4alkyl or C1-C4haloalkyl. More preferably, R1 and R2 each independently are hydrogen, C1-C4alkyl or C1-C4haloalkyl. More preferably, R1 and R2 each independently are hydrogen, methyl or halomethyl, more preferably hydrogen, methyl or trifluoromethyl. Even more preferably, R1 is trifluoromethyl. Preferably, R2 is methyl.


R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, halogen, cyano, C1-C4alkyl or C1-C4haloalkyl. Preferably, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, halogen, C1-C4alkyl or C1-C4haloalkyl. More preferably, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, C1-C4alkyl or C1-C4haloalkyl. Even more preferably, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen or methyl.


R11, R15 and R16 each independently are hydrogen, C1-C4alkyl, C3-C5cycloalkyl or C1-C4alkoxy. Preferably, R11, R15 and R16 each independently are hydrogen, C1-C4alkyl or Cr C4alkoxy. More preferably, R11, R15 and R16 each independently are hydrogen or C1-C4alkyl. More preferably, R11, R15 and R16 each independently are hydrogen or methyl. Even more preferably, R11, R15 and R16 each independently are hydrogen.


R12 is heteroaryl (preferably heteroaryl as defined above, more preferably furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl) which can be optionally substituted with 1 to 4 R23 and each R23 independently is halogen, hydroxyl, cyano, mercapto, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C4haloalkoxy, C1-C4alkylthio, N(R24)2, phenyl or heteroaryl (preferably heteroaryl as defined above, more preferably pyridyl, pyrazinyl, pyridazinyl or pyrimidinyl), wherein the phenyl and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy. R12 may be group (a)


or is group (a)




embedded image



wherein q is 1, 2, or 3 and e is 1 or 2.


Preferably, R12 is heteroaryl (preferably heteroaryl as defined above, more preferably furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl) which can be optionally substituted with 1 to 3 R23 and each R23 independently is halogen, hydroxyl, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C4haloalkoxy, C1-C4alkylthio, N(R24)2, phenyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein the phenyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidinyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy. R12 may also be group (a) with R23 similarly defined.


More preferably, R12 is heteroaryl (preferably heteroaryl as defined above, more preferably furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl) which can be optionally substituted with 1 to 3 R23 and each R23 independently is halogen, hydroxyl, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, N(R24)2, phenyl or pyridyl, wherein the phenyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy. R12 may also be group (a) with R23 similarly defined.


More preferably, R12 is furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl, wherein the furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl are optionally substituted with 1 to 3 R23 and each R23 independently is halogen, hydroxyl, cyano, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, N(R24)2, phenyl or pyridyl, wherein the phenyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy. R12 may also be group (a) with R23 similarly defined.


Yet more preferably, R12 is thiadiazolyl or pyridyl, wherein the thiadiazolyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, C1-C4alkyl and C1-C4alkoxy.


Most preferably, R12 is pyridyl, optionally substituted with 1 to 3 substituents independently selected from halogen and hydroxyl.


Each R24 independently is hydrogen, cyano, C1-C4alkyl, C1-C4alkylcarbonyl, C1-C4haloalkylcarbonyl, C1-C4alkylsulfonyl or C1-C4haloalkylsulfonyl. Preferably, each R24 independently is hydrogen, C1-C4alkyl, C1-C4alkylcarbonyl, C1-C4alkylsulfonyl or C1-C4haloalkylsulfonyl. More preferably, each R24 independently is hydrogen, C1-C4alkyl, C1-C4alkylcarbonyl or C1-C4alkylsulfonyl. Even more preferably, each R24 independently is hydrogen or C1-C4alkylsulfonyl.


In one group of compounds R1 is trifluoromethyl, R2 is methyl, R3 and R4 are hydrogen and G1 is O.


In one group of compounds G2 is S, Y1 is N and Y2 is CH.


In one group of compounds p is 1 and n is 2.


In one group of compounds R5, R6, R7, R8, R9 and R10 are hydrogen.


In one group of compounds Q is —C(═O)-z, wherein z indicates the bond that is connected to R12.


In one group of compounds R12 is heteroaryl (preferably heteroaryl as defined above, more preferably furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl) substituted with hydroxyl and optionally substituted with one or two further substituents. Preferably, the hydroxyl is at the ortho position. Preferably, one of the further substituents is halogen and is preferably at the meta position adjacent to the hydroxyl.


In one group of compounds R12 is group (a).


In group (a) any carbon atom in either ring may be substituted by R23.


For the avoidance of doubt, when n is 1 and p is 1 compounds of formula I have the formula according to formula IA:




embedded image



in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, G1, G2, T, Y1, Y2 and Q have the definitions as described for formula I.


When n is 2 and p is 1, compounds of formula I have the formula according to formula IB:




embedded image



in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 G1, G2, T, Y1, Y2 and Q have the definitions as described for formula I.


When n is 1 and p is 2, compounds of formula I have the formula according to formula IC:




embedded image



in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, G1, G2, T, Y1, Y2 and Q have the definitions as described for formula I.


The invention also relates to compounds of formula IA, formula IB and formula IC as shown above.


The invention also relates to compounds of formula ID:




embedded image



in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, G1, G2, T, Y1, Y2 and Q have the definitions as described for formula I. Preferred definitions of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, G1, G2, T, Y1, Y2 and Q are as defined for formula I.


The invention also relates to compounds of formula IE:




embedded image



in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and Q have the definitions as described for formula I. Preferred definitions of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 are Q are as defined for formula I.


The invention also relates to compounds of formula IF:




embedded image



wherein T is CH or N, preferably CH;


R11 is CH3 or H; and


R1, R2 and R12 have the definitions as described for formula I. Preferred definitions of R1, R2 and R12 are as defined for formula I.


The invention also relates to compounds of formula IG:




embedded image



wherein T is CH or N, preferably CH;


R11 is CH3 or H; and


R12 has the definition as described for formula I. Preferred definitions of R12 are as defined for formula I.


The invention includes compounds of formula II:




embedded image



in which R5, R6, R7, R8, R9, R10, R11, R12, G2, T, Y1, Y2, Q, n and p are as defined for formula I and R18 is hydrogen or a protecting group such as alkylcarbonyl, benzyl or alkoxycarbonyl, e.g. C1-C4 alkylcarbonyl, benzyl or C1-C4 alkoxycarbonyl, in particular acetyl, benzyl or tert-butoxycarbonyl. These compounds, including salts or N-oxides thereof, are useful as intermediates in the synthesis of compounds of formula I. Preferred definitions of R5, R6, R7, R8, R9, R10, R11, R12, G2, T, Y1, Y2, n and p are as defined for formula I.


The invention also includes compounds of formula III:




embedded image



wherein R1, R2, R3, R4, R5, R6, R7, R9, R10, R11, R12, G1, G2, Y1, Y2, Q, n and p are as defined for formula I. These compounds, including salts or N-oxides thereof, are useful as intermediates in the synthesis of compounds of formula I. Preferred definitions of R1, R2, R3, R4, R5, R6, R7, R9, R10, R11, R12, G1, G2, Y1, Y2 n and p are as defined for formula I.


The invention also includes compounds of formula Va:




embedded image



wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, G1, G2, T, Y1, Y2, n and p are as defined for formula I. These compounds, including salts or N-oxides thereof, are useful as intermediates in the synthesis of compounds of formula I. Preferred definitions of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, G1, G2, T, Y1, Y2, n and p are as defined for formula I.


Preferred individual compounds of formula I are:

  • 4-Hydroxy-[1,2,5]thiadiazole-3-carboxylic acid (2-{4-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-thiazol-4-yl)-amide (Compound No. 1.g.020);
  • 3-Hydroxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.023);
  • 4-Chloro-3-hydroxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.024);
  • 3-Hydroxy-4-methoxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.025)
  • 4,6-Dichloro-3-hydroxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.026);
  • 5-Chloro-4-hydroxy-N-(2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-nicotinamide (Compound No. 1.g.031);
  • 2-Chloro-3-hydroxy-N-(2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-isonicotinamide (Compound No. 1.g.035);
  • 3-Hydroxy-pyridine-2-carboxylic acid methyl-(2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.h.023);
  • 4-Chloro-3-hydroxy-pyridine-2-carboxylic acid methyl-(2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.h.024);
  • 3-Hydroxy-pyridine-2-carboxylic acid (2-{4-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-thiazol-4-yl)-amide (Compound No. 1.n.023); and
  • 4-Chloro-3-hydroxy-pyridine-2-carboxylic acid (2-{4-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperazin-1-yl}-thiazol-4-yl)-amide (Compound No. 1.n.024).


Compounds of the present invention can be made as shown in the following schemes. Throughout this description, the group M, wherein R1, R2, R3, R4 and G1 are as defined for formula I, stands for:




embedded image


The compounds of formula IV, wherein R5, R6, R7, R8, R9, R10, R11, R12, G2, Q, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula V, wherein R5, R6, R7, R8, R9, R10, R11, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with a compound of formula VI, wherein R12 and Q are as defined for formula I and R19 is hydroxy, halogen, preferably fluoro, chloro or bromo, or alkoxy, such as methoxy, ethoxy. This is shown in Scheme 1.




embedded image


The compounds of formula VII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula VIII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an azide, such as diphenyl phosphoryl azide and subsequent Curtius rearrangement of the resulting acyl azide with an alcohol R20—OH, wherein R20 is C1-C4alkyl or optionally substituted aryl, and following carbamate cleavage with a mineral acid, such as hydrochloric acid, sulfuric acid or an organic acid, such as trifluoroacetic acid. This is shown in Scheme 2.




embedded image


The compounds of formula VIII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by saponification of a compound of formula IX, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I, R20 is C1-C4alkyl or optionally substituted aryl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with a base such as sodium hydroxide, potassium hydroxide or lithium hydroxide. This is shown in Scheme 3.




embedded image


The compounds of formula X, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, Y2, n and p are as defined for formula I, R21 is C1-C4alkyl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula XI, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an alkyl halide R21-Hal, wherein R21 is C1-C4alkyl and Hal is halogen, preferably chloro or bromo. This is shown in Scheme 4.




embedded image


The compounds of formula XI, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula VIII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an azide, such as diphenyl phosphoryl azide and subsequent Curtius rearrangement of the resulting acyl azide with a Grignard reagent R12—Mg-Hal, wherein R12 is as defined for formula I and Hal is halogen, preferably chloro, bromo or iodo, or a boronic acid R12—B(OH)2, wherein R12 is as defined for formula I and a catalyst, such as bis(1,5-cyclooctadiene)rhodium(I) hydroxide. This is shown in Scheme 5.




embedded image


The compounds of formula XII, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, Y2, n and p are as defined for formula I, R21 is C1-C4alkyl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula XIII, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an alkyl halide R21-Hal, wherein R21 is C1-C4alkyl and Hal is halogen, preferably chloro or bromo. This is shown in Scheme 6.




embedded image


The compounds of formula XIII, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula VIII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an azide, such as diphenyl phosphoryl azide and subsequent Curtius rearrangement of the resulting acyl azide with an alcohol R12—OH, wherein R12 is as defined for formula I as defined for formula I. This is shown in Scheme 7.




embedded image



The compounds of formula XIV, wherein R5, R6, R7, R5, R9, R10, R12, G2, T, Y2, n and p are as defined for formula I, R21 is C1-C4alkyl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula XV, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an alkyl halide R21-Hal, wherein R21 is C1-C4alkyl and Hal is halogen, preferably chloro or bromo. This is shown in Scheme 8.




embedded image


The compounds of formula XV, wherein R5, R6, R7, R8, R9, R10, R12, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by transformation of a compound of formula VIII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with an azide, such as diphenyl phosphoryl azide and subsequent Curtius rearrangement of the resulting acyl azide with an amine R12—NH2, wherein R12 is as defined for formula I. This is shown in Scheme 9.




embedded image


The compounds of formula XVI, wherein R5, R6, R7, R9, R10, R11, R12, G2, Q, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by reduction of a compound of formula XVII, wherein R5, R6, R7, R9, R10, R11, R12, G2, Q, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with hydrogen and a catalyst, such as palladium on charcoal, platinum or raney-nickel. This is shown in Scheme 10.




embedded image


The compounds of formula XVII, wherein R5, R6, R7, R9, R10, R11, R12, G2, Q, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by cross coupling of a compound of formula XVIII, wherein R5, R6, R7, R9, R10, n and p are as defined for formula I, R22 is B(OH)2 or an ester of such a boronic acid and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with a compound of formula XIX, wherein R11, R12, G2, Q, Y1, Y2, n and p are as defined for formula I and Hal is halogen, preferably chloro, bromo or iodo, and a transition metal, such as tetrakis(triphenylphosphine)palladium, and a ligand. This is shown in Scheme 11.




embedded image


Alternatively, the compounds of formula XVII, wherein R5, R6, R7, R9, R10, R11, R12, G2, Q, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by cross coupling of a compound of formula XX, wherein R5, R6, R7, R9, R10, G2, Y1, and Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with a compound of formula XXI, wherein R11, R12 and Q are as defined for formula I and a catalyst, such as Pd(OAc)2 or copperiodide with a ligand such as Xantphos or dimethylethylenediamine and. This is shown in Scheme 12.




embedded image


The compounds of formula XX, wherein R5, R6, R7, R9, R10, G2, Y1, Y2, n and p are as defined for formula I and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by cross coupling of a compound of formula XVIII, wherein R5, R6, R7, R9, R10, n and p are as defined for formula I, R22 is B(OH)2 or an ester of such a boronic acid and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with a compound of formula XXII, wherein G2, Y1 and Y2 are as defined for formula I and Hal is halogen, preferably iodo or bromo, and a transition metal, such as bis-(triphenylphosphine)palladium(II) chloride. This is shown in Scheme 13.




embedded image


The compounds of formula XXIII, wherein R5, R6, R7, R9, R10, G2, Y1, Y2, n and p are as defined for formula I, R20 is C1-C4alkyl or optionally substituted aryl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by reduction of a compound of formula XXIV, wherein R5, R6, R7, R9, R10, G2, Y1, Y2, n and p are as defined for formula I, R20 is C1-C4alkyl or optionally substituted aryl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with hydrogen and a catalyst, such as palladium on charcoal, platinum or raney-nickel. This is shown in Scheme 14.




embedded image


The compounds of formula XXIV, wherein R5, R6, R7, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I, R20 is C1-C4alkyl or optionally substituted aryl and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, can be obtained by cross coupling of a compound of formula XVIII, wherein R5, R6, R7, R9, R10, n and p are as defined for formula I, R22 is B(OH)2 or an ester of such a boronic acid and A is hydrogen, a protecting group such as acetyl, benzyl or tert-butoxycarbonyl or a group M, with a compound of formula XXV, wherein G2, Y1 and Y2 are as defined for formula I, R20 is C1-C4alkyl or optionally substituted aryl and Hal is halogen, preferably chloro, bromo or iodo and a transition metal, such as bis-(triphenylphosphine)palladium(II) chloride. This is shown in Scheme 15.




embedded image



The compounds of formula XXVI, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, G1, G2, T, Y1, Y2, n and p are as defined for formula I and R20 is C1-C4alkyl or optionally substituted aryl can be obtained by transformation of a compound of formula XXVII, wherein R1, R2, R3, R4 and G1 are as defined for formula I and R19 is hydroxyl, halogen, preferably fluoro, chloro or bromo or alkoxy, such as methoxy, ethoxy, with a compound of formula XXVIII, wherein R5, R6, R7, R8, R9, R10, G2, T, Y1, Y2, n and p are as defined for formula I and R20 is C1-C4alkyl or optionally substituted aryl. This is shown in Scheme 16.




embedded image



The compounds of formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, G1, G2, Q, T, Y1, Y2, n and p are as defined for formula I can be obtained by transformation of a compound of formula XXVII, wherein R1, R2, R3, R4 and G1 are as defined for formula I and R19 is hydroxyl, halogen, preferably fluoro, chloro or bromo or alkoxy, such as methoxy, ethoxy, with a compound of formula XXIX, wherein R5, R6, R7, R8, R9, R10, R11, R12, G2, Q, T, Y1, Y2, n and p are as defined for formula I. This is shown in Scheme 17.




embedded image


Surprisingly, it has now been found that the novel compounds of formula I have, for practical purposes, a very advantageous level of biological activity for protecting plants against diseases that are caused by fungi.


The compounds of formula I can be used in the agricultural sector and related fields of use e.g. as active ingredients for controlling plant pests or on non-living materials for control of spoilage microorganisms or organisms potentially harmful to man. The novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and may be used for protecting numerous cultivated plants. The compounds of formula I can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms.


It is also possible to use compounds of formula I as dressing agents for the treatment of plant propagation material, e.g., seed, such as fruits, tubers or grains, or plant cuttings (for example rice), for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil. The propagation material can be treated with a composition comprising a compound of formula I before planting: seed, for example, can be dressed before being sown. The active ingredients according to the invention can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation. The composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated.


Furthermore the compounds according to present invention can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.


In addition, the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint.


The compounds of formula I are, for example, effective against the phytopathogenic fungi of the following classes: Fungi imperfecti (e.g. Alternaria spp.), Basidiomycetes (e.g. Corticium spp., Ceratobasidium spp., Waitea spp., Thanatephorus spp., Rhizoctonia spp., Hemileia spp., Puccinia spp., Phakopsora spp., Ustilago spp., Tilletia spp.), Ascomycetes (e.g. Venturia spp., Blumeria spp., Erysiphe spp., Podosphaera spp., Uncinula spp., Monilinia spp., Sclerotinia spp., Colletotrichum spp., Glomerella spp., Fusarium spp., Gibberella spp., Monographella spp., Phaeosphaeria spp., Mycosphaerella spp., Cercospora spp., Pyrenophora spp., Rhynchosporium spp., Magnaporthe spp., Gaeumannomyces spp., Oculimacula spp., Ramularia spp., Botryotinia spp.) and Oomycetes (e.g. Phytophthora spp., Pythium spp., Plasmopara spp., Peronospora spp., Pseudoperonospora spp. Bremia spp). Outstanding activity is observed against downy mildew (e.g. Plasmopara viticola) and late blight (e.g. Phytophthora infestans). Furthermore, the novel compounds of formula I are effective against phytopathogenic gram negative and gram positive bacteria (e.g. Xanthomonas spp, Pseudomonas spp, Erwinia amylovora, Ralstonia spp.) and viruses (e.g. tobacco mosaic virus).


Within the scope of present invention, target crops and/or useful plants to be protected typically comprise the following species of plants: cereal (wheat, barley, rye, oat, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pomes, drupes and soft fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); leguminous plants (beans, lentils, peas, soybeans); oil plants (rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans, groundnuts); cucumber plants (pumpkins, cucumbers, melons); fibre plants (cotton, flax, hemp, jute); citrus fruit (oranges, lemons, grapefruit, mandarins); vegetables (spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, paprika); lauraceae (avocado, cinnamomum, camphor) or plants such as tobacco, nuts, coffee, eggplants, sugar cane, tea, pepper, vines, hops, bananas and natural rubber plants, as well as turf and ornamentals.


The useful plants and/or target crops in accordance with the invention include conventional as well as genetically enhanced or engineered varieties such as, for example, insect resistant (e.g. Bt. and VIP varieties) as well as disease resistant, herbicide tolerant (e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®) and nematode tolerant varieties. By way of example, suitable genetically enhanced or engineered crop varieties include the Stoneville 5599BR cotton and Stoneville 4892BR cotton varieties.


The term “useful plants” and/or “target crops” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.


The term “useful plants” and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.


The term “useful plants” and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called “pathogenesis-related proteins” (PRPs, see e.g. EP-A-0 392 225). Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0 392 225, WO 95/33818, and EP-A-0 353 191. The methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.


The term “locus” of a plant as used herein is intended to embrace the place on which the plants are growing, where the plant propagation materials of the plants are sown or where the plant propagation materials of the plants will be placed into the soil. An example for such a locus is a field, on which crop plants are growing.


The term “plant propagation material” is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably “plant propagation material” is understood to denote seeds.


The compounds of formula I may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they may be conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.


Suitable carriers and adjuvants, e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.


The compounds of formula I are normally used in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non-selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.


The compounds of formula I may be used in the form of fungicidal compositions for controlling or protecting against phytopathogenic microorganisms, comprising as active ingredient at least one compound of formula I or of at least one preferred individual compound as above-defined, in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants.


The invention provides a fungicidal composition comprising at least one compound formula I an agriculturally acceptable carrier and optionally an adjuvant. An agricultural acceptable carrier is for example a carrier that is suitable for agricultural use. Agricultural carriers are well known in the art. Preferably said fungicidal compositions may comprise at least one additional fungicidal active ingredient in addition to the compound of formula I.


The compound of formula (I) may be the sole active ingredient of a composition or it may be admixed with one or more additional active ingredients such as a pesticide, fungicide, synergist, herbicide or plant growth regulator where appropriate. An additional active ingredient may, in some cases, result in unexpected synergistic activities. Examples of suitable additional active ingredients include the following: Azoxystrobin (131860-33-8), Dimoxystrobin (149961-52-4), Enestrobin (238410-11-2), Fluoxastrobin (193740-76-0), Kresoxim-methyl (143390-89-0), Metominostrobin (133408-50-1), Orysastrobin (248593-16-0), Picoxystrobin (117428-22-5), Pyraclostrobin (175013-18-0), trifloxystrobin (141517-21-7), Azaconazole (60207-31-0), Bromuconazole (116255-48-2), Cyproconazole (94361-06-5), Difenoconazole (119446-68-3), Diniconazole (83657-24-3), Diniconazole-M (83657-18-5), Epoxiconazole (13385-98-8), Fenbuconazole (114369-43-6), Fluquinconazole (136426-54-5), Flusilazole (85509-19-9), Flutriafol (76674-21-0), Hexaconazole (79983-71-4), Imazalil (58594-72-2), Imibenconazole (86598-92-7), Ipconazole (125225-28-7), Metconazole (125116-23-6), Myclobutanil (88671-89-0), Oxpoconazole (174212-12-5), Pefurazoate (58011-68-0), Penconazole (66246-88-6), Prochloraz (67747-09-5), Propiconazole (60207-90-1), Prothioconazole (178928-70-6), Simeconazole (149508-90-7), Tebuconazole (107534-96-3), Tetraconazole (112281-77-3), Triadimefon (43121-43-3), Triadimenol (55219-65-3), Triflumizole (99387-89-0), Triticonazole (131983-72-7), Diclobutrazol (76738-62-0), Etaconazole (60207-93-4), Fluconazole (86386-73-4), Fluconazole-cis (112839-32-4), Thiabendazole (148-79-8), Quinconazole (103970-75-8), Fenpiclonil (74738-17-3), Fludioxonil (131341-86-1), Cyprodinil (121552-61-2), Mepanipyrim (110235-47-7), Pyrimethanil (53112-28-0), Aldimorph (91315-15-0), Dodemorph (1593-77-7), Fenpropimorph (67564-91-4), Tridemorph (81412-43-3), Fenpropidin (67306-00-7), Spiroxamine (118134-30-8), Isopyrazam (881685-58-1), Sedaxane (874967-67-6), Bixafen (581809-46-3), Penthiopyrad (183675-82-3), Fluxapyroxad (907204-31-3), Boscalid (188425-85-6), Penflufen (494793-67-8), Fluopyram (658066-35-4), Mandipropamid (374726-62-2), Benthiavalicarb (413615-35-7), Dimethomorph (110488-70-5), Chlorothalonil (1897-45-6), Fluazinam (79622-59-6), Dithianon (3347-22-6), Metrafenone (220899-03-6), Tricyclazole (41814-78-2), Mefenoxam (70630-17-0), Metalaxyl (57837-19-1), Acibenzolar (126448-41-7) (Acibenzolar-5-methyl (126448-41-7)), Mancozeb (8018-01-7), Ametoctradine (865318-97-4) Cyflufenamid (180409-60-3), and Kresoxim-methyl (143390-89-0), Ipconazole (125225-28-7), Amisulbrom (348635-87-0), Cyflufenamid (180409-60-3), Ethaboxam (16650-77-3), Fluopicolide (239110-15-7), Fluthianil (304900-25-2), Isotianil (224049-04-1), Proquinazid (189278-12-4), Valiphenal (283159-90-0), 1-methyl-cyclopropene (3100-04-7), Trifloxystrobin (141517-21-7), Sulfur (7704-34-9), Copper ammoniumcarbonate (CAS 33113-08-5); Copper oleate (CAS 1120-44-1); Folpet (133-07-3), Quinoxyfen (124495-18-7), Captan (133-06-2), Fenhexamid (126833-17-8), Glufosinate and its salts (51276-47-2, 35597-44-5 (S-isomer)), Glyphosate (1071-83-6) and its salts (69254-40-6 (Diammonium), 34494-04-7 (Dimethylammonium), 38641-94-0 (Isopropylammonium), 40465-66-5 (Monoammonium), 70901-20-1 (Potassium), 70393-85-0 (Sesquisodium), 81591-81-3 (Trimesium)), 1,3-Dimethyl-1H-pyrazole-4-carboxylic acid (2-dichloromethylene-3-ethyl-1-methyl-indan-4-yl)-amide, 1,3-Dimethyl-1H-pyrazole-4-carboxylic acid (4′-methylsulfanyl-biphenyl-2-yl)-amide, 1,3-Dimethyl-4H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-2-methoxy-1-methyl-ethyl]-amide, (5-Chloro-2,4-dimethyl-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, (5-Bromo-4-chloro-2-methoxy-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, 2-{2-[(E)-3-(2,6-Dichloro-phenyl)-1-methyl-prop-2-en-(E)-ylideneaminooxymethyl]-phenyl}-2-[(Z)-methoxyimino]-N-methyl-acetamide, 3-[5-(4-Chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine.


Another aspect of invention is related to the use of a compound of formula I or of a preferred individual compound as above-defined, of a composition comprising at least one compound of formula I or at least one preferred individual compound as above-defined, or of a fungicidal mixture comprising at least one compound of formula I or at least one preferred individual compound as above-defined, in admixture with other fungicides, as described above, for controlling or preventing infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or non-living materials by phytopathogenic microorganisms, preferably fungal organisms.


A further aspect of invention is related to a method of controlling or preventing an infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or of non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a compound of formula I or of a preferred individual compound as above-defined as active ingredient to the plants, to parts of the plants or to the locus thereof, to the propagation material thereof, or to any part of the non-living materials.


Controlling or preventing means reducing infestation by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.


A preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, which comprises the application of a compound of formula I, or an agrochemical composition which contains at least one of said compounds, is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen. However, the compounds of formula I can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds of formula I may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.


A formulation, e.g. a composition containing the compound of formula I, and, if desired, a solid or liquid adjuvant or monomers for encapsulating the compound of formula I, may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).


The agrochemical formulations and/or compositions will usually contain from 0.1 to 99% by weight, preferably from 0.1 to 95% by weight, of the compound of formula I, 99.9 to 1% by weight, preferably 99.8 to 5% by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant.


Advantageous rates of application are normally from 5 g to 2 kg of active ingredient (a.i.) per hectare (ha), preferably from 10 g to 1 kg a.i./ha, most preferably from 20 g to 600 g a.i./ha. When used as seed drenching agent, convenient dosages are from 10 mg to 1 g of active substance per kg of seeds.


Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations.


The following non-limiting example illustrates the above-described invention in more detail.







EXAMPLE 1

This Example illustrates the preparation of 3-hydroxy-4-methoxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.025)


a) Preparation of 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazole-4-carboxylic acid ethyl ester

To a solution of (5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetic acid (9.1 g, 36.1 mmol) in DMF (100 mL) is added diisopropylethylamine (45 mL, 216 mmol), followed by O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (15.5 g, 39.7 mmol). After stirring 15 min at RT, 2-piperidin-4-yl-thiazole-4-carboxylic acid ethyl ester hydrochloride (10 g, 36.1 mmol) is added to the reaction mixture. After stirring overnight at RT, solvent is evaporated and the resulting yellow oil is dissolved in ethylacetate (300 mL), washed with saturated aqueous sodium bicarbonate solution (300 mL), 1M HCl solution (300 mL), and brine (100 mL). The organic layer is dried over sodium sulfate, filtered, and evaporated under reduced pressure. The crude mixture is purified by column chromatography on silica gel (dichloromethane/methanol 10:1) to give 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazole-4-carboxylic acid ethyl ester (13.6 g, 88%). 1H-NMR (400 MHz, CDCl3): δ=1.40 (t, 3H), 1.70-1.85 (m, 2H), 2.16-2.30 (m, 2H), 2.32 (s, 3H), 2.79-2.89 (m, 1H), 3.22-3.43 (m, 1H), 4.03-4.12 (m, 1H), 4.42 (q, 3H), 4.54-4.69 (m, 1H), 4.93-5.08 (2 d, 2H (diastereotopic)), 6.35 (s, 1H), 8.10 (br, 1H). MS: m/z=209 (M+1).


b) Preparation of 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazole-4-carboxylic acid

To a solution of 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazole-4-carboxylic acid ethyl ester (2.67 g, 6.2 mmol) in THF (20 mL) is added aqueous solution of sodium hydroxide (2 M, 4.65 mL, 9.3 mmol) at RT. After stirring 3 h at RT, the reaction mixture is acidified with 2M aqueous solution of HCl until pH 2-3, and the solution is extracted with ethylacetate (20 mL). The aqueous layer is re-extracted with ethylacetate (20 mL) and the combined organic layers are washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure to give 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazole-4-carboxylic acid (2.33 g, 94%), which can be used in the next step without further purification. 1H-NMR (400 MHz, d6-acetone): δ=1.69-1.82 (m, 1H), 1.87-2.02 (m, 1H), 2.16-2.37 (m, 2H), 2.38 (s, 3H), 2.89-2.99 (m, 1H), 3.38-3.48 (m, 2H), 4.14-4.22 (m, 1H), 4.50-4.69 (m, 1H), 5.20-5.36 (2 d, 2H (diastereotopic)), 6.41, (s, 1H), 8.34 (s, 1H). MS: m/z=403 (M+1).


c) Preparation of 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-carbamic acid tert-butyl ester

To a solution of 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazole-4-carboxylic acid (9.95 g, 24.74 mmol) in tert-butanol (90 mL) is added triethylamine (8.2 mL, 56.9 mmol). After stirring 30 min. at RT, diphenylphosphoryl azide (10.9 mL, 49.5 mmol) is added and the reaction mixture is divided in 6 portions and each portion was irradiated under microwave (100° C., 15 min.). After cooling to RT, all portions are combined and water (3 mL) is added to the reaction mixture and stirred for 30 minutes. Acetonitrile (40 mL) is then added, followed by addition of basic Amberlyst A21. After stirring overnight at RT, the resin is filtered off, and solvents are evaporated under reduced pressure. The residue is purified by column chromatography on silica gel (ethyl acetate/cyclohexane 7:3) to give 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-carbamic acid tert-butyl ester (9.6 g, 82%). 1H-NMR (400 MHz, CDCl3): δ=1.53 (s, 9H), 1.68-1.78 (m, 2H), 2.08-2.19 (m, 2H), 2.32 (s, 3H), 2.85-2.95 (m, 1H), 3.10-3.20 (m, 1H), 3.23-3.34 (m, 1H), 3.97-4.04 (m, 1H), 4.50-4.58 (m, 1H), 4.93-5.05 (2d, 2H, diastereotopic protons), 6.33 (s, 1H), 7.10 (br, 1H), 7.30 (s, 1H). MS: m/z=474 (M+1).


d) Preparation of 1-[4-(4-amino-thiazol-2-yl)-piperidin-1-yl]-2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-ethanone

To a solution of 2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-carbamic acid tert-butyl ester (9.6 g, 20.3 mmol) is added a solution of 4M HCl in dioxane (50 mL, 203 mmol)) at RT. After stirring 2 days at RT, the solvent is evaporated under reduced pressure. The resulting yellowish foam is triturated with diethylether, and filtered to give 1-[4-(4-Amino-thiazol-2-yl)-piperidin-1-yl]-2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-ethanone hydrochloride salt, which is suspended in aqueous saturated sodium bicarbonate (500 mL). After stirring 30 min. at RT, the reaction mixture is extracted with ethylacetate (500 mL). The combined organic layers are washed with water (100 mL) and brine (100 mL), filtered, dried over sodium sulfate, and evaporated under reduced pressure to give 1-[4-(4-amino-thiazol-2-yl)-piperidin-1-yl]-2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-ethanone (5.63 g, 74%). 1H-NMR (400 MHz, CDCl3): δ=1.65-1.80 (m, 2H), 2.08-2.20 (m, 2H), 2.31 (s, 3H), 2.81-2.91 (m, 1H), 3.08-3.18 (m, 1H), 3.21-3.32 (m, 1H), 3.95-4.08 (m, 3H), 4.50-4.59 (m, 1H), 4.93-5.04 (2d, 2H, diastereotopic protons), 5.84 (s, 1H), 6.32 (s, 1H). MS: m/z=374 (M+1).


e) Preparation of 3-hydroxy-4-methoxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.025)

To a solution of 3-hydroxy-4-methoxy-pyridine-2-carboxylic acid acid (70 mg, 0.34 mmol) in 4 ml of acetonitrile triethylamine (0.13 mL, 0.96 mmol), 1-ethyl-3-dimethylaminopropyl)carbodiimide (77 mg, 0.41 mmol) and 1-hydroxy-7-azabenzotriazole (53 mg, 0.38 mmol) were added at RT. After stirring 15 min at RT, 1-[4-(4-amino-thiazol-2-yl)-piperidin-1-yl]-2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-ethanone (120 mg, 0.32 mmol) was added to the reaction mixture. After stirring 16 h at RT, the reaction mixture was diluted with 20 ml of ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate solution, 1 M hydrochloric acid and brine, dried over sodium sulfate and evaporated under reduced pressure. The remainder was purified by column chromatography on silica gel (ethylacetate/cyclohexane 1:1 to 8:2) to give 3-hydroxy-4-methoxy-pyridine-2-carboxylic acid (2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-amide (Compound No. 1.g.025) as a beige solid. 1H-NMR (400 MHz, CDCl3): δ=1.64-1.77 (m, 2H), 2.05-2.16 (m, 2H), 2.27 (s, 3H), 2.81-2.89 (m, 1H), 3.12-3.28 (m, 2H), 3.92 (s, 3H), 3.94-3.99 (m, 1H), 4.44-4.51 (m, 1H), 4.93 (d, 2H), 6.27 (s, 1H), 6.89 (d, 1H), 7.59 (s, 1H), 8.00 (d, 1H). MS: m/z=525 (M+1).


Table 1 below illustrates examples of individual compounds of formula I according to the invention.









TABLE 1







individual compounds of formula I according to the invention











Com-






pound






No.
R1
G1
Q
R12





001
F3C—
O
—C(═O)—


embedded image







002
F3C—
O
—C(═O)—


embedded image







003
F3C—
O
—C(═O)—


embedded image







004
F3C—
O
—C(═O)—


embedded image







005
F3C—
O
—C(═O)—


embedded image







006
F3C—
O
—C(═O)—


embedded image







007
F3C—
O
—C(═O)—


embedded image







008
F3C—
O
—C(═O)—


embedded image







009
F3C—
O
—C(═O)—


embedded image







010
F3C—
O
—C(═O)—


embedded image







011
F3C—
O
—C(═O)—


embedded image







012
F3C—
O
—C(═O)—


embedded image







013
F3C—
O
—C(═O)—


embedded image







014
F3C—
O
—C(═O)—


embedded image







015
F3C—
O
—C(═O)—


embedded image







016
F3C—
O
—C(═O)—


embedded image







017
F3C—
O
—C(═O)—


embedded image







018
F3C—
O
—C(═O)—


embedded image







019
F3C—
O
—C(═O)—


embedded image







020
F3C—
O
—C(═O)—


embedded image







021
F3C—
O
—C(═O)—


embedded image







022
F3C—
O
—C(═O)—


embedded image







023
F3C—
O
—C(═O)—


embedded image







024
F3C—
O
—C(═O)—


embedded image







025
F3C—
O
—C(═O)—


embedded image







026
F3C—
O
—C(═O)—


embedded image







027
F3C—
O
—C(═O)—


embedded image







028
F3C—
O
—C(═O)—


embedded image







029
F3C—
O
—C(═O)—


embedded image







030
F3C—
O
—C(═O)—


embedded image







031
F3C—
O
—C(═O)—


embedded image







032
F3C—
O
—C(═O)—


embedded image







033
F3C—
O
—C(═O)—


embedded image







034
F3C—
O
—C(═O)—


embedded image







035
F3C—
O
—C(═O)—


embedded image







036
F3C—
O
—C(═O)—


embedded image







037
F3C—
O
—C(═O)—


embedded image







038
F3C—
O
—C(═O)—


embedded image







039
F3C—
O
—C(═O)—


embedded image







040
F3C—
O
—C(═O)—


embedded image







041
F3C—
O
—C(═O)—


embedded image







042
F3C—
O
—C(═O)—


embedded image







043
F3C—
O
—C(═O)—


embedded image







044
F3C—
O
—C(═O)—


embedded image







045
F3C—
O
—C(═O)—


embedded image







046
F3C—
O
—C(═O)—


embedded image







047
F3C—
O
—C(═O)—


embedded image







048
F3C—
O
—C(═O)—


embedded image







049
F3C—
O
—C(═O)—


embedded image







050
F3C—
O
—C(═O)—


embedded image







051
F3C—
S
—C(═O)—


embedded image







052
F3C—
S
—C(═O)—


embedded image







053
F3C—
S
—C(═O)—


embedded image







054
F3C—
S
—C(═O)—


embedded image







055
F3C—
S
—C(═O)—


embedded image







056
F3C—
S
—C(═O)—


embedded image







057
F3C—
S
—C(═O)—


embedded image







058
F3C—
S
—C(═O)—


embedded image







059
F3C—
S
—C(═O)—


embedded image







060
F3C—
S
—C(═O)—


embedded image







061
F3C—
S
—C(═O)—


embedded image







062
F3C—
S
—C(═O)—


embedded image







063
F3C—
S
—C(═O)—


embedded image







064
F3C—
S
—C(═O)—


embedded image







065
F3C—
S
—C(═O)—


embedded image







066
F3C—
S
—C(═O)—


embedded image







067
F3C—
S
—C(═O)—


embedded image







068
F3C—
S
—C(═O)—


embedded image







069
F3C—
S
—C(═O)—


embedded image







070
F3C—
S
—C(═O)—


embedded image







071
F3C—
S
—C(═O)—


embedded image







072
F3C—
S
—C(═O)—


embedded image







073
F3C—
S
—C(═O)—


embedded image







074
F3C—
S
—C(═O)—


embedded image







075
F3C—
S
—C(═O)—


embedded image







076
F3C—
S
—C(═O)—


embedded image







077
F3C—
S
—C(═O)—


embedded image







078
F3C—
S
—C(═O)—


embedded image







079
F3C—
S
—C(═O)—


embedded image







080
F3C—
S
—C(═O)—


embedded image







081
F3C—
S
—C(═O)—


embedded image







082
F3C—
S
—C(═O)—


embedded image







083
F3C—
S
—C(═O)—


embedded image







084
F3C—
S
—C(═O)—


embedded image







085
F3C—
S
—C(═O)—


embedded image







086
F3C—
S
—C(═O)—


embedded image







087
F3C—
S
—C(═O)—


embedded image







088
F3C—
S
—C(═O)—


embedded image







089
F3C—
S
—C(═O)—


embedded image







090
F3C—
S
—C(═O)—


embedded image







091
F3C—
S
—C(═O)—


embedded image







092
F3C—
S
—C(═O)—


embedded image







093
F3C—
S
—C(═O)—


embedded image







094
F3C—
S
—C(═O)—


embedded image







095
F3C—
S
—C(═O)—


embedded image







096
F3C—
S
—C(═O)—


embedded image







097
F3C—
S
—C(═O)—


embedded image







098
F3C—
S
—C(═O)—


embedded image







099
F3C—
S
—C(═O)—


embedded image







100
F3C—
S
—C(═O)—


embedded image







101
F3C—
O
—C(═S)—


embedded image







102
F3C—
O
—C(═S)—


embedded image







103
F3C—
O
—C(═S)—


embedded image







104
F3C—
O
—C(═S)—


embedded image







105
F3C—
O
—C(═S)—


embedded image







106
F3C—
O
—C(═S)—


embedded image







107
F3C—
O
—C(═S)—


embedded image







108
F3C—
O
—C(═S)—


embedded image







109
F3C—
O
—C(═S)—


embedded image







110
F3C—
O
—C(═S)—


embedded image







111
F3C—
O
—C(═S)—


embedded image







112
F3C—
O
—C(═S)—


embedded image







113
F3C—
O
—C(═S)—


embedded image







114
F3C—
O
—C(═S)—


embedded image







115
F3C—
O
—C(═S)—


embedded image







116
F3C—
O
—C(═S)—


embedded image







117
F3C—
O
—C(═S)—


embedded image







118
F3C—
O
—C(═S)—


embedded image







119
F3C—
O
—C(═S)—


embedded image







120
F3C—
O
—C(═S)—


embedded image







121
F3C—
O
—C(═S)—


embedded image







122
F3C—
O
—C(═S)—


embedded image







123
F3C—
O
—C(═S)—


embedded image







124
F3C—
O
—C(═S)—


embedded image







125
F3C—
O
—C(═S)—


embedded image







126
F3C—
O
—C(═S)—


embedded image







127
F3C—
O
—C(═S)—


embedded image







128
F3C—
O
—C(═S)—


embedded image







129
F3C—
O
—C(═S)—


embedded image







130
F3C—
O
—C(═S)—


embedded image







131
F3C—
O
—C(═S)—


embedded image







132
F3C—
O
—C(═S)—


embedded image







133
F3C—
O
—C(═S)—


embedded image







134
F3C—
O
—C(═S)—


embedded image







135
F3C—
O
—C(═S)—


embedded image







136
F3C—
O
—C(═S)—


embedded image







137
F3C—
O
—C(═S)—


embedded image







138
F3C—
O
—C(═S)—


embedded image







139
F3C—
O
—C(═S)—


embedded image







140
F3C—
O
—C(═S)—


embedded image







141
F3C—
O
—C(═S)—


embedded image







142
F3C—
O
—C(═S)—


embedded image







143
F3C—
O
—C(═S)—


embedded image







144
F3C—
O
—C(═S)—


embedded image







145
F3C—
O
—C(═S)—


embedded image







146
F3C—
O
—C(═S)—


embedded image







147
F3C—
O
—C(═S)—


embedded image







148
F3C—
O
—C(═S)—


embedded image







149
F3C—
O
—C(═S)—


embedded image







150
F3C—
O
—C(═S)—


embedded image







151
H3C—
O
—C(═O)—


embedded image







152
H3C—
O
—C(═O)—


embedded image







153
H3C—
O
—C(═O)—


embedded image







154
H3C—
O
—C(═O)—


embedded image







155
H3C—
O
—C(═O)—


embedded image







156
H3C—
O
—C(═O)—


embedded image







157
H3C—
O
—C(═O)—


embedded image







158
H3C—
O
—C(═O)—


embedded image







159
H3C—
O
—C(═O)—


embedded image







160
H3C—
O
—C(═O)—


embedded image







161
H3C—
O
—C(═O)—


embedded image







162
H3C—
O
—C(═O)—


embedded image







163
H3C—
O
—C(═O)—


embedded image







164
H3C—
O
—C(═O)—


embedded image







165
H3C—
O
—C(═O)—


embedded image







166
H3C—
O
—C(═O)—


embedded image







167
H3C—
O
—C(═O)—


embedded image







168
H3C—
O
—C(═O)—


embedded image







169
H3C—
O
—C(═O)—


embedded image







170
H3C—
O
—C(═O)—


embedded image







171
H3C—
O
—C(═O)—


embedded image







172
H3C—
O
—C(═O)—


embedded image







173
H3C—
O
—C(═O)—


embedded image







174
H3C—
O
—C(═O)—


embedded image







175
H3C—
O
—C(═O)—


embedded image







176
H3C—
O
—C(═O)—


embedded image







177
H3C—
O
—C(═O)—


embedded image







178
H3C—
O
—C(═O)—


embedded image







179
H3C—
O
—C(═O)—


embedded image







180
H3C—
O
—C(═O)—


embedded image







181
H3C—
O
—C(═O)—


embedded image







182
H3C—
O
—C(═O)—


embedded image







183
H3C—
O
—C(═O)—


embedded image







184
H3C—
O
—C(═O)—


embedded image







185
H3C—
O
—C(═O)—


embedded image







186
H3C—
O
—C(═O)—


embedded image







187
H3C—
O
—C(═O)—


embedded image







188
H3C—
O
—C(═O)—


embedded image







189
H3C—
O
—C(═O)—


embedded image







190
H3C—
O
—C(═O)—


embedded image







191
H3C—
O
—C(═O)—


embedded image







192
H3C—
O
—C(═O)—


embedded image







193
H3C—
O
—C(═O)—


embedded image







194
H3C—
O
—C(═O)—


embedded image







195
H3C—
O
—C(═O)—


embedded image







196
H3C—
O
—C(═O)—


embedded image







197
H3C—
O
—C(═O)—


embedded image







198
H3C—
O
—C(═O)—


embedded image







199
H3C—
O
—C(═O)—


embedded image







200
H3C—
O
—C(═O)—


embedded image







201
H3C—
S
—C(═O)—


embedded image







202
H3C—
S
—C(═O)—


embedded image







203
H3C—
S
—C(═O)—


embedded image







204
H3C—
S
—C(═O)—


embedded image







205
H3C—
S
—C(═O)—


embedded image







206
H3C—
S
—C(═O)—


embedded image







207
H3C—
S
—C(═O)—


embedded image







208
H3C—
S
—C(═O)—


embedded image







209
H3C—
S
—C(═O)—


embedded image







210
H3C—
S
—C(═O)—


embedded image







211
H3C—
S
—C(═O)—


embedded image







212
H3C—
S
—C(═O)—


embedded image







213
H3C—
S
—C(═O)—


embedded image







214
H3C—
S
—C(═O)—


embedded image







215
H3C—
S
—C(═O)—


embedded image







216
H3C—
S
—C(═O)—


embedded image







217
H3C—
S
—C(═O)—


embedded image







218
H3C—
S
—C(═O)—


embedded image







219
H3C—
S
—C(═O)—


embedded image







220
H3C—
S
—C(═O)—


embedded image







221
H3C—
S
—C(═O)—


embedded image







222
H3C—
S
—C(═O)—


embedded image







223
H3C—
S
—C(═O)—


embedded image







224
H3C—
S
—C(═O)—


embedded image







225
H3C—
S
—C(═O)—


embedded image







226
H3C—
S
—C(═O)—


embedded image







227
H3C—
S
—C(═O)—


embedded image







228
H3C—
S
—C(═O)—


embedded image







229
H3C—
S
—C(═O)—


embedded image







230
H3C—
S
—C(═O)—


embedded image







231
H3C—
S
—C(═O)—


embedded image







232
H3C—
S
—C(═O)—


embedded image







233
H3C—
S
—C(═O)—


embedded image







234
H3C—
S
—C(═O)—


embedded image







235
H3C—
S
—C(═O)—


embedded image







236
H3C—
S
—C(═O)—


embedded image







237
H3C—
S
—C(═O)—


embedded image







238
H3C—
S
—C(═O)—


embedded image







239
H3C—
S
—C(═O)—


embedded image







240
H3C—
S
—C(═O)—


embedded image







241
H3C—
S
—C(═O)—


embedded image







242
H3C—
S
—C(═O)—


embedded image







243
H3C—
S
—C(═O)—


embedded image







244
H3C—
S
—C(═O)—


embedded image







245
H3C—
S
—C(═O)—


embedded image







246
H3C—
S
—C(═O)—


embedded image







247
H3C—
S
—C(═O)—


embedded image







248
H3C—
S
—C(═O)—


embedded image







249
H3C—
S
—C(═O)—


embedded image







250
H3C—
S
—C(═O)—


embedded image







251
H3C—
O
—C(═S)—


embedded image







252
H3C—
O
—C(═S)—


embedded image







253
H3C—
O
—C(═S)—


embedded image







254
H3C—
O
—C(═S)—


embedded image







255
H3C—
O
—C(═S)—


embedded image







256
H3C—
O
—C(═S)—


embedded image







257
H3C—
O
—C(═S)—


embedded image







258
H3C—
O
—C(═S)—


embedded image







259
H3C—
O
—C(═S)—


embedded image







260
H3C—
O
—C(═S)—


embedded image







261
H3C—
O
—C(═S)—


embedded image







262
H3C—
O
—C(═S)—


embedded image







263
H3C—
O
—C(═S)—


embedded image







264
H3C—
O
—C(═S)—


embedded image







265
H3C—
O
—C(═S)—


embedded image







266
H3C—
O
—C(═S)—


embedded image







267
H3C—
O
—C(═S)—


embedded image







268
H3C—
O
—C(═S)—


embedded image







269
H3C—
O
—C(═S)—


embedded image







270
H3C—
O
—C(═S)—


embedded image







271
H3C—
O
—C(═S)—


embedded image







272
H3C—
O
—C(═S)—


embedded image







273
H3C—
O
—C(═S)—


embedded image







274
H3C—
O
—C(═S)—


embedded image







275
H3C—
O
—C(═S)—


embedded image







276
H3C—
O
—C(═S)—


embedded image







277
H3C—
O
—C(═S)—


embedded image







278
H3C—
O
—C(═S)—


embedded image







279
H3C—
O
—C(═S)—


embedded image







280
H3C—
O
—C(═S)—


embedded image







281
H3C—
O
—C(═S)—


embedded image







282
H3C—
O
—C(═S)—


embedded image







283
H3C—
O
—C(═S)—


embedded image







284
H3C—
O
—C(═S)—


embedded image







285
H3C—
O
—C(═S)—


embedded image







286
H3C—
O
—C(═S)—


embedded image







287
H3C—
O
—C(═S)—


embedded image







288
H3C—
O
—C(═S)—


embedded image







289
H3C—
O
—C(═S)—


embedded image







290
H3C—
O
—C(═S)—


embedded image







291
H3C—
O
—C(═S)—


embedded image







292
H3C—
O
—C(═S)—


embedded image







293
H3C—
O
—C(═S)—


embedded image







294
H3C—
O
—C(═S)—


embedded image







295
H3C—
O
—C(═S)—


embedded image







296
H3C—
O
—C(═S)—


embedded image







297
H3C—
O
—C(═S)—


embedded image







298
H3C—
O
—C(═S)—


embedded image







299
H3C—
O
—C(═S)—


embedded image







300
H3C—
O
—C(═S)—


embedded image







301
F3C—
O
—C(═O)—


embedded image







302
F3C—
S
—C(═O)—


embedded image







303
F3C—
O
—C(═S)—


embedded image







304
F3C—
S
—C(═S)—


embedded image







305
F3C—
O
—C(═O)O—


embedded image







306
F3C—
O
—C(═O)N—


embedded image







307
H3C
O
—C(═O)—


embedded image







308
H3C
S
—C(═O)—


embedded image







309
H3C
O
—C(═S)—


embedded image







310
H3C
S
—C(═S)—


embedded image







311
F2HC—
O
—C(═O)—


embedded image







312
F2HC—
S
—C(═O)—


embedded image







313
F2HC—
O
—C(═S)—


embedded image







314
F2HC—
S
—C(═S)—


embedded image







315
F3C—
O
—C(═O)—


embedded image












where


a) 315 compounds of formula (I.a):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


b) 315 compounds of formula (I.b):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


c) 315 compounds of formula (I.c):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


d) 315 compounds of formula (I.d):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


e) 315 compounds of formula (I.e):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


f) 315 compounds of formula (I.f):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


g) 315 compounds of formula (I.g):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


h) 315 compounds of formula (I.h):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


i) 315 compounds of formula (I.i):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


j) 315 compounds of formula (I.j):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


k) 315 compounds of formula (I.k):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


m) 315 compounds of formula (I.m):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


n) 315 compounds of formula (I.n):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


o) 315 compounds of formula (I.o):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


p) 315 compounds of formula (I.p):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


q) 315 compounds of formula (I.q):




embedded image



Wherein G1, Q, R1 and R12 are as defined in Table 1.


r) 315 compounds of formula (I.r):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


s) 315 compounds of formula (I.s):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


t) 315 compounds of formula (I.t):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


u) 315 compounds of formula (I.u):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


v) 315 compounds of formula (I.v):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


w) 315 compounds of formula (I.w):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


x) 315 compounds of formula (I.x):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


y) 315 compounds of formula (I.y):




embedded image



wherein G1, Q, R1 and R12 are as defined in Table 1.


Throughout this description, LC/MS means Liquid Chromatography Mass Spectroscopy and the description of the apparatus and the method is: (HP 1100 HPLC from Agilent, Phenomenex Gemini C18, 3 μm particle size, 110 Angström, 30×3 mm column, 1.7 mL/min., 60° C., H2O+0.05% HCOOH (95%)/CH3CN/MeOH 4:1+0.04% HCOOH (5%)—2 min.—CH3CN/MeOH 4:1+0.04% HCOOH (5%)—0.8 min., ZQ Mass Spectrometer from Waters, ionization method: electrospray (ESI), Polarity: positive ions, Capillary (kV) 3.00, Cone (V) 30.00, Extractor (V) 2.00, Source Temperature (° C.) 100, Desolvation Temperature (° C.) 250, Cone Gas Flow (L/Hr) 50, Desolvation Gas Flow (L/Hr) 400)).


Table 2 shows selected LC/MS data for compounds of Table 1.









TABLE 2







LC/MS data for compounds of Table 1










Compound No.
LC/MS







I.g.001
Rt = 2.47 min; MS: m/z = 467.87 (M + 1)



I.g.002
Rt = 3.28 min; MS: m/z = 543.87 (M + 1)



I.g.005
Rt = 2.73 min; MS: m/z = 483.85 (M + 1)



I.g.006
Rt = 2.96 min; MS: m/z = 560.83 (M + 1)



I.g.008
Rt = 2.87 min; MS: m/z = 513.86 (M + 1)



I.g.009
Rt = 2.56 min; MS: m/z = 495.93 (M + 1)



I.g.010
Rt = 2.97 min; MS: m/z = 557.91 (M + 1)



I.g.011
Rt = 3.02 min; MS: m/z = 558.88 (M + 1)



I.g.013
Rt = 1.80 min; MS: m/z = 467.93 (M + 1)



I.g.016
Rt = 3.32 min; MS: m/z = 544.87 (M + 1)



I.g.017
Rt = 3.36 min; MS: m/z = 574.86 (M + 1)



I.g.018
Rt = 1.52 min; MS: m/z = 530.36 (M + 1)



I.g.019
Rt = 2.44 min; MS: m/z = 485.86 (M + 1)



I.g.022
Rt = 2.99 min; MS: m/z = 492.92 (M + 1)



I.g.023
Rt = 1.91 min; MS: m/z = 495(M + 1)



I.g.024
Rt = 1.90 min; MS: m/z = 529 (M + 1)



I.g.025
Rt = 1.62 min; MS: m/z = 525(M + 1)



I.g.027
Rt = 2.16 min; MS: m/z = 478.91 (M + 1)



I.g.028
Rt = 1.29 min; MS: m/z = 495.39 (M + 1)



I.g.029
Rt = 2.71 min; MS: m/z = 524.84 (M + 1)



I.g.030
Rt = 1.59 min; MS: m/z = 495(M + 1)



I.g.034
Rt = 1.56 min; MS: m/z = 495(M + 1)



I.g.040
Rt = 1.57 min; MS: m/z = 530 (M + 1)



I.g.042
Rt = 1.41 min; MS: m/z = 524.39 (M + 1)



I.g.044
Rt = 3.35 min; MS: m/z = 528.87 (M + 1)



I.g.050
Rt = 3.03 min; MS: m/z = 529.91 (M + 1)



I.g.315
Rt = 1.92 min; MS: m/z = 569.75 (M + 1)










The compounds according to the present invention can be prepared according to the above-mentioned reaction schemes, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I).


BIOLOGICAL EXAMPLES

Phytophthora infestans/Tomato/Leaf Disc Preventative (Tomato Late Blight)

Tomato leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks are incubated at 16° C. and 75% rh under a light regime of 24 h darkness followed by 12 h light/12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5-7 days after application).


Compounds I.g.001, I.g.006, I.g.010, I.g.018, I.g.022, I.g.023, I.g.025, I.g.028, I.g.042, I.g.044, I.g.050 and I.g.315 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Phytophthora infestans/Potato/Preventative (Potato Late Blight)


2-week old potato plants cv. Bintje are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants are inoculated by spraying them with a sporangia suspension 2 days after application. The inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (5-7 days after application).


Compounds I.g.001, I.g.010, I.g.018, I.g.023, I.g.025, I.g.044 and I.g.050 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Phytophthora infestans/Potato/Long Lasting (Potato Late Blight)


2-week old potato plants cv. Bintje are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants are inoculated by spraying them with a sporangia suspension 6 days after application. The inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (9-11 days after application).


Compounds I.g.001, I.g.023, I.g.025, I.g.044 and I.g.050 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Plasmopara viticola/Grape/Leaf Disc Preventative (Grape Downy Mildew)


Grape vine leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks are incubated at 19° C. and 80% rh under a light regime of 12 h light/12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (6-8 days after application).


Compounds I.g.001, I.g.005, I.g.006, I.g.009, I.g.019, I.g.022, I.g.023, I.g.042 and I.g.044 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Plasmopara viticola/Grape/Preventative (Grape Downy Mildew)


5-week old grape seedlings cv. Gutedel are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants plants are inoculated by spraying a sporangia suspension on their lower leaf surface one day after application. The inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (6-8 days after application).


Compounds I.g.001, I.g.005, I.g.006, I.g.009, I.g.022, I.g.023 and I.g.042 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Plasmopara viticola/Grape/Long Lasting (Grape Downy Mildew)


5-week old grape seedlings cv. Gutedel are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants are inoculated by spraying a sporangia suspension on their lower leaf surface 6 days after application. The inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (11-13 days after application).


Compounds I.g.005, I.g.006, I.g.009, I.g.022 and I.g.042 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Pythium ultimum/Liquid Culture (Seedling Damping Off)


Mycelia fragments and oospores of a newly grown liquid culture of the fungus are directly mixed into nutrient broth (PDB potato dextrose broth). After placing a (DMSO) solution of test compound into a microtiter plate (96-well format), the nutrient broth containing the fungal mycelia/spore mixture is added. The test plates are incubated at 24° C. and the inhibition of growth is determined photometrically 2-3 days after application.


Compounds I.g.018, I.g.023, I.g.025 and I.g.042 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.



Pythium ultimum/Cotton/Soil Drench (Seedling Damping Off)


The test is carried out in plastic containers (650 ml volume) using a mixture of (50% Vermiculit+sterile 50% Cugy soil)+10% v/v water. 10 seeds (cotton, cv. Sure Grow 747) are sown in 2 rows of 5 seeds per container (3 replicates for evaluation of the activity, 3 replicates for evaluation of phytotox). Application is carried out directly after sowing by pouring 10 ml compound diluted in water per row over the seeds. Just afterwards the seeds are covered with a thin layer of the same soil and the inoculation is happening. Pythium ultimum is cultivated for 14 days on carrot slices in Roux bottles. For inoculation, the content of the Roux bottles is mixed and homogenously dispensed over the plastic containers without further filtering (70 ml suspension per container). Incubation conditions: 20° C., 12 h/12 h day/night period in the greenhouse. The activity of a compound is assessed as percent disease control relative to untreated check plants when an appropriate level of disease damage appears in untreated check plants (13-16 days after application).


Compounds I.g.023, I.g.025, I.g.042 and I.g.315 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

Claims
  • 1. A compound of formula I:
  • 2. The compound according to claim 1, wherein G1 and G2 are independently O or S;T is CR13 or N;Y1 is N;Y2 is CR14 or N;Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z, —C(═O)—N(R15)-z or —C(═S)—N(R16)-z, in each case z indicates the bond that is connected to R12;n is 1 or 2;p is 1;R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, halogen, C1-C4alkyl or C1-C4haloalkyl;R11, R15 and R16 each independently are hydrogen, C1-C4alkyl or C1-C4alkoxy;R12 is heteroaryl which can be optionally substituted with 1 to 3 R23, or group (a);each R23 independently is halogen, hydroxyl, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, N(R24)2, phenyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein the phenyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidinyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; andeach R24 independently is hydrogen, C1-C4alkyl, C1-C4alkylcarbonyl, C1-C4alkylsulfonyl or C1-C4haloalkylsulfonyl;q is 1, 2 or 3;e is 1 or 2.
  • 3. The compound according to claim 1, wherein G1 is O;G2 is O or S;T is CR13 or N;Y1 is N;Y2 is CR14 or N;Q is —C(═O)-z, —C(═S)-z, —C(═O)—O-z or —C(═O)—N(R15)-z, in each case z indicates the bond that is connected to R12;n is 1 or 2;p is 1;R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13 and R14 each independently are hydrogen, C1-C4alkyl or C1-C4haloalkyl;R11 and R15 each independently are hydrogen or C1-C4alkyl;R12 is heteroaryl which can be optionally substituted with 1 to 3 R23, or group (a);each R23 independently is halogen, hydroxyl, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, N(R24)2, phenyl or pyridyl, wherein the phenyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; andeach R24 independently is hydrogen, C1-C4alkyl, C1-C4alkylcarbonyl or C1-C4alkylsulfonyl;q is 1, 2 or 3;e is 1 or 2.
  • 4. The compound according to claim 1, wherein G1 is O;G2 is S;T is CH or N;Y1 is N;Y2 is CH or N;Q is —C(═O)-z, —C(═S)-z or —C(═O)—N(R15)-z, in each case z indicates the bond that is connected to R12;n is 1 or 2;p is 1;R1 and R2 each independently are hydrogen, methyl or trifluoromethyl;R3, R4, R5, R6, R7, R8, R9 and R10 each independently are hydrogen or methyl;R11 and R15 each independently are hydrogen or methyl;R12 is furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl or quinoxalinyl, or group (a), wherein the furyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrazolyl, imidazothiazolyl, quinolinyl and quinoxalinyl are optionally substituted with 1 to 3 R23;each R23 independently is halogen, hydroxyl, cyano, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, N(R24)2, phenyl and pyridyl, wherein the phenyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy; andeach R24 independently is hydrogen or C1-C4alkylsulfonyl;q is 1, 2 or 3;e is 1 or 2.
  • 5. The compound according to claim 1, wherein G1 is O;G2 is S;T is CH;Y1 is N;Y2 is CH;Q is —C(═O)-z or —C(═S)-z, in each case z indicates the bond that is connected to R12;n is 2;p is 1;R1 and R2 each independently are hydrogen, methyl or trifluoromethyl;R3, R4, R5, R6, R7, R8, R9 and R10 each independently are hydrogen or methyl;R11 is hydrogen or methyl; andR12 is thiadiazolyl or pyridyl, wherein the thiadiazolyl and pyridyl are optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxyl, C1-C4alkyl and C1-C1alkoxy.
  • 6. The compound according to claim 1, wherein R1 is trifluoromethyl, R2 is methyl, R3 and R4 are hydrogen and G1 is O.
  • 7. The compound according to claim 1, wherein G2 is S, Y1 is N and Y2 is CH.
  • 8. The compound according to claim 1, wherein p is 1 and n is 2.
  • 9. The compound according to claim 1, wherein R5, R6, R7, R8, R9 and R19 are hydrogen.
  • 10. The compound according to claim 1, wherein Q is —C(═O)-z, wherein z indicates the bond that is connected to R12.
  • 11. The compound according to claim 1, wherein R12 is heteroaryl substituted with hydroxyl and optionally substituted with one or two further substituents.
  • 12. The compound according to claim 11, wherein the hydroxyl is at the ortho position.
  • 13. A fungicidal composition comprising at least one compound as defined in claim 1 and an agriculturally acceptable carrier, optionally comprising an adjuvant, and optionally comprising at least one additional fungicidally active compound.
  • 14. A method of controlling or preventing an infestation of plants, propagation material thereof, harvested crops or non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, which comprises the application of a compound as defined in claim 1, to the plant, to parts of the plants or to the locus thereof, to propagation material thereof or to any part of the non-living materials.
Priority Claims (2)
Number Date Country Kind
10192493 Nov 2010 EP regional
11153989 Feb 2011 EP regional
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2011/071037 11/25/2011 WO 00 8/13/2013
Publishing Document Publishing Date Country Kind
WO2012/069633 5/31/2012 WO A
Foreign Referenced Citations (2)
Number Date Country
2007014290 Feb 2007 WO
2008091580 Jul 2008 WO
Non-Patent Literature Citations (1)
Entry
International Search Report, International Application No. PCT/EP2011/071037, completion date: Jan. 11, 2011.
Related Publications (1)
Number Date Country
20130324544 A1 Dec 2013 US